MIAMI, Dec. 18, 2007 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN) announced today that BioSource Therapeutics, Inc. (BST), its wholly-owned subsidiary, has named Dr. Robert Keller, MD, MS, FACP, AAHIVS as head of its Scientific Advisory Board effective January 1, 2008. BST is the maker of Nutraplete(tm) Therapeutic Drink Mix, the first dietary supplement product designed specifically for people living with HIV/AIDS.
"I'm pleased to join the team introducing Nutraplete to the medical community," said Dr. Keller. "Nutraplete is an important advancement in ensuring proper nutritional supplementation for HIV/AIDS patients. This "functional food" encourages restoration of lean body mass, can inhibit pro-oxidative stress, and improves immune function. Nutraplete is based on an impressive body of research and data that helps support its efficacy in people afflicted with HIV/AIDS. In addition, BST has a remarkable team of scientists, clinicians and business professionals who are helping create measurable, positive change in the course of this epidemic."
Dr. Keller has devoted over 25 years researching and studying the human immune system, and owns several patents. He has been named as one of the world's 2,000 Outstanding Scientists of the 21st Century, and has served on the scientific review panels for the National Institutes of Health and the US Veterans Administration. He has served on the faculties of the Mayo Graduate School of Medicine, the University of Wisconsin and the Medical College of Wisconsin (Marquette University). Dr. Keller was elected to The Board of Governors of the American Academy of HIV medicine, and serves on the Scientific Advisory Board of several Biotech companies. He has more than 100 articles published in various scientific and medical journals. The Consumers Research Council named Dr. Keller as one of America's "Top Physicians in 2003, 2004 and 2005 2006 and 2007" in the fields of Internal Medicine, Immunology and Hematology.
"We are privileged to have someone of Dr. Keller's caliber bringing his wealth of experience to BST," said David Miller, President & CEO of BST. "His distinguished career highlights a special focus in the clinical, nutritional and research aspects of HIV/AIDS, and he's committed to BST's mission to establish Nutraplete as the medical community's preferred dietary supplement. He will also be directing BST's upcoming Clinical Evaluation of Nutraplete."
About Nutraplete
Nutraplete is the first therapeutic dietary supplement designed specifically for people living with HIV/AIDS. It is a multi-nutritional supplement, designed to address AIDS Wasting Syndrome. It works in conjunction with antiviral therapies and assists patients in the adherence and tolerance of treatments. Nutraplete is a "functional food" that encourages the restoration of lean body mass, can inhibit pro-oxidative stress, and improves immune function. Nutraplete is available by prescription, and has started the application process for inclusion with Medicaid and AIDS Drugs Assistance Program (ADAP) formularies. Nutraplete is distributed nationally by Allion Healthcare, Inc. (Nasdaq:ALLI) under its MOMS Pharmacy trade name. www.momspharmacy.com.
For more information: www.nutraplete.com
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. (Pink Sheets:GLSN) is currently a non-reporting over-the-counter publicly traded company. GLSN identifies and acquires new and innovative nutraceutical product and dietary supplement companies with outstanding growth potential. GLSN's focus is in the emerging scientific field of advanced nutritional supplements designed to support traditional medical treatments and therapies. BioSource Therapeutics, Inc. (BST), a GLSN subsidiary, is an entrepreneurial life sciences company. BST specializes in the formulation, manufacturing, marketing and distribution of innovative dietary supplements that benefit people undergoing medical treatments and therapies.
For more information on Dr. Keller: http://www.robkellermd.org/keller.htm
Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "project," "intend," "expect" "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements.
Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.